BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 17075122)

  • 21. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
    Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
    Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
    Ramlau R; Gorbunova V; Ciuleanu TE; Novello S; Ozguroglu M; Goksel T; Baldotto C; Bennouna J; Shepherd FA; Le-Guennec S; Rey A; Miller V; Thatcher N; Scagliotti G
    J Clin Oncol; 2012 Oct; 30(29):3640-7. PubMed ID: 22965962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel.
    Schuette W; Nagel S; Blankenburg T; Lautenschlaeger C; Hans K; Schmidt EW; Dittrich I; Schweisfurth H; von Weikersthal LF; Raghavachar A; Reissig A; Serke M
    J Clin Oncol; 2005 Nov; 23(33):8389-95. PubMed ID: 16293869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
    Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
    J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Goy A; Younes A; McLaughlin P; Pro B; Romaguera JE; Hagemeister F; Fayad L; Dang NH; Samaniego F; Wang M; Broglio K; Samuels B; Gilles F; Sarris AH; Hart S; Trehu E; Schenkein D; Cabanillas F; Rodriguez AM
    J Clin Oncol; 2005 Feb; 23(4):667-75. PubMed ID: 15613697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
    Ma C; Mandrekar SJ; Alberts SR; Croghan GA; Jatoi A; Reid JM; Hanson LJ; Bruzek L; Tan AD; Pitot HC; Erlichman C; Wright JJ; Adjei AA
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):207-15. PubMed ID: 16763792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.
    Segawa Y; Kiura K; Takigawa N; Kamei H; Harita S; Hiraki S; Watanabe Y; Sugimoto K; Shibayama T; Yonei T; Ueoka H; Takemoto M; Kanazawa S; Takata I; Nogami N; Hotta K; Hiraki A; Tabata M; Matsuo K; Tanimoto M
    J Clin Oncol; 2010 Jul; 28(20):3299-306. PubMed ID: 20530281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
    Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
    Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP; Fossella F
    Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
    Besse B; Planchard D; Veillard AS; Taillade L; Khayat D; Ducourtieux M; Pignon JP; Lumbroso J; Lafontaine C; Mathiot C; Soria JC
    Lung Cancer; 2012 Apr; 76(1):78-83. PubMed ID: 22186627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH; Kim JH; Lee JA; Shin HC; Kim HJ; Song HH; Jung JY; Kim HY; Choi DR; Kim HS; Park YI; Zang DY
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
    Segawa Y; Kiura K; Hotta K; Takigawa N; Tabata M; Matsuo K; Yoshioka H; Hayashi H; Kawai H; Aoe K; Maeda T; Ueoka H; Tanimoto M
    J Thorac Oncol; 2010 Sep; 5(9):1430-4. PubMed ID: 20651615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019).
    Belvedere O; Follador A; Rossetto C; Merlo V; Defferrari C; Sibau AM; Aita M; Dal Bello MG; Meduri S; Gaiardo M; Fasola G; Grossi F
    Eur J Cancer; 2011 Jul; 47(11):1653-9. PubMed ID: 21514147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).
    Kudoh S; Takeda K; Nakagawa K; Takada M; Katakami N; Matsui K; Shinkai T; Sawa T; Goto I; Semba H; Seto T; Ando M; Satoh T; Yoshimura N; Negoro S; Fukuoka M
    J Clin Oncol; 2006 Aug; 24(22):3657-63. PubMed ID: 16877734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II randomized trial of tri-weekly versus days 1 and 8 weekly docetaxel as a second-line treatment of advanced non-small cell lung cancer.
    Lai CL; Tsai CM; Chiu CH; Wang GS; Su WJ; Chen YM; Perng RP
    Jpn J Clin Oncol; 2005 Dec; 35(12):700-6. PubMed ID: 16303792
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
    Kim YH; Kim JS; Choi YH; In KH; Park HS; Hong DS; Jeong TJ; Lee YY; Nam E; Lee SN; Lee KS; Kim HK
    Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in non-small cell lung cancer patients who failed previous chemotherapy.
    Chou KT; Chen YM; Shih JF; Perng RP; Tsai CM; Whang-Peng J
    Lung Cancer; 2008 Jan; 59(1):64-8. PubMed ID: 17764779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
    Kourousis C; Androulakis N; Kakolyris S; Souglakos J; Maltezakis G; Metaxaris G; Chalkiadakis G; Samonis G; Vlachonikolis J; Georgoulias V
    Cancer; 1998 Nov; 83(10):2083-90. PubMed ID: 9827712
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
    Hanna N; Neubauer M; Yiannoutsos C; McGarry R; Arseneau J; Ansari R; Reynolds C; Govindan R; Melnyk A; Fisher W; Richards D; Bruetman D; Anderson T; Chowhan N; Nattam S; Mantravadi P; Johnson C; Breen T; White A; Einhorn L; ;
    J Clin Oncol; 2008 Dec; 26(35):5755-60. PubMed ID: 19001323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.